Autologous Transplantation in Turkey

Which Diseases May Be Treated With Autologous Stem Cell Transplantation?

Autologous transplantation is mainly considered for selected cancers where high-dose therapy followed by stem cell rescue has an established role.

• Multiple myeloma: Autologous transplantation is used within selected treatment pathways for eligible patients with this plasma-cell cancer.

• Lymphoma: Certain Hodgkin and non-Hodgkin lymphoma pathways can include autologous transplantation after appropriate previous treatment.

• Selected solid tumors: Stem cell transplantation can have roles in particular testicular cancers and selected pediatric tumors.

• Other diseases: Eligibility depends on diagnosis-specific evidence rather than the general availability of transplantation technology.

A diagnosis alone does not establish suitability. Disease status, previous therapy, organ function, and treatment alternatives also influence transplant decisions.

How Are Stem Cells Collected Before Autologous Transplantation in Turkey?

Stem cells for autologous transplantation are commonly collected from the patient’s bloodstream using an apheresis system. Treatment beforehand may help move additional stem cells from bone marrow into peripheral blood. During apheresis, blood passes through equipment that separates the required stem cells. Other blood components are returned to the patient during the collection process. Turkish public transplant centers document coordination with therapeutic apheresis units for peripheral stem cell collection. Collected cells then undergo laboratory processing before storage or transplantation. The collection plan depends on the disease, previous treatment, circulating cell numbers, and the transplant center’s clinical protocol.

Why Are Autologous Stem Cells Cryopreserved Before Transplantation?

Autologous stem cells are cryopreserved so they remain available after the patient receives intensive conditioning treatment. Conditioning can severely reduce normal blood-forming cells within the bone marrow. The previously collected cells are therefore stored before this treatment begins. Turkish public transplant centers document stem cell laboratories that process and cryopreserve collected peripheral stem cells. Storage also requires controlled handling and traceability procedures. Turkey’s current tissue and cell framework regulates processes including preservation, storage, processing, and traceability for covered human cells. Cryopreservation does not itself treat the cancer. It preserves the collected stem cell product until the planned reinfusion.

Does Autologous Transplantation Require HLA Matching or a Stem Cell Donor?

No, autologous transplantation does not require another stem cell donor or donor-recipient HLA matching. The collected cells come from the patient receiving the transplant. This removes the donor-search process required for allogeneic transplantation. Classic donor-derived graft-versus-host disease is associated with allogeneic transplantation, not standard autologous transplantation. However, autologous transplantation has different limitations and risks. NCI notes a small possibility that collected material can contain cancer cells that are later reinfused. Intensive conditioning can also cause serious treatment-related complications. The absence of a donor therefore simplifies one part of transplantation but does not remove overall transplant risk.

What Happens During Conditioning and Stem Cell Reinfusion?

Conditioning uses intensive treatment before the stored stem cells are returned to the patient. In cancer treatment, conditioning commonly includes high-dose chemotherapy selected for the underlying disease. This treatment targets cancer cells but can also severely damage normal blood-forming cells. The cryopreserved autologous stem cells are subsequently thawed and infused through an intravenous catheter. Transplant teams often call the reinfusion date “day zero.” The cells then travel through the bloodstream toward the bone marrow. Medical monitoring continues because blood counts initially remain low. Supportive treatment can include infection prevention, transfusion support, symptom management, and repeated laboratory testing.

What Does Engraftment Mean After an Autologous Transplant?

Engraftment means the returned stem cells have started producing new blood cells within the patient’s bone marrow. Doctors follow this process through repeated blood counts after transplantation. Increasing neutrophil levels provide an important sign of early blood-cell recovery. Platelets and red blood cells can recover on different schedules. Engraftment should not be confused with complete recovery from transplantation. A patient can show improving blood counts while still requiring close medical monitoring. Infection risk, nutritional problems, organ effects, and other complications can remain relevant. The transplant team therefore evaluates both blood-count recovery and the patient’s wider clinical condition before changing follow-up intensity.

Which Complications Need Monitoring After Autologous Transplantation?

Autologous transplantation requires monitoring for complications caused mainly by conditioning, immune suppression, and delayed blood-cell recovery.

• Infection: Reduced white blood cells can temporarily increase vulnerability to bacterial, viral, and fungal infections.

• Bleeding: Low platelet levels can increase bleeding or bruising during early recovery.

• Mucosal toxicity: Mouth sores, nausea, vomiting, or appetite problems can follow intensive conditioning treatment.

• Organ effects: Treatment can affect organs including the liver, kidneys, lungs, or heart in selected patients.

• Late effects: Fertility problems, bone changes, or secondary cancers can require longer-term monitoring.

Individual risks depend on conditioning, diagnosis, previous treatments, age, organ function, and other medical factors.

Is Engraftment the Same as Full Immune Recovery?

No, engraftment does not mean the immune system has completely recovered after an autologous transplant. Blood counts can improve before immune function returns to its previous capacity. NCI states that full immune recovery can take several months after autologous transplantation. This distinction matters when planning infection precautions, vaccination, travel, and follow-up. A patient may therefore feel physically improved while remaining immunologically vulnerable. Recovery also differs between individuals and treatment protocols. Patients should follow their transplant team’s infection-prevention guidance after discharge. Decisions about returning to crowded environments or international travel should reflect individual immune status rather than blood counts alone.

Why Can Revaccination Be Needed After Autologous Transplantation?

Revaccination can be required because hematopoietic stem cell transplantation can reduce immunity created by vaccinations received before treatment. CDC guidance treats hematopoietic cell transplant recipients as needing renewed vaccination schedules for selected vaccines. For example, Hib vaccination is restarted after successful transplantation regardless of previous Hib vaccination history. The timing of different vaccines varies according to immune recovery and vaccine type. Live vaccines require additional consideration because significant immune suppression can change their safety profile. Patients should therefore receive a written post-transplant vaccination plan. International patients should also coordinate this schedule with clinicians who will provide follow-up after they return home.

What Should International Patients Prepare Before Autologous Transplantation in Turkey?

International patients should provide complete disease and treatment records before arranging autologous transplantation in Turkey. Important documents include pathology, bone marrow reports, molecular findings, and recent laboratory results. Previous chemotherapy and radiotherapy records can affect transplant eligibility and stem cell collection planning. Patients should also provide current medications, infection history, and significant medical conditions. Original imaging files may be relevant for reassessing disease status. The transplant center should determine whether additional testing is required before travel. Patients should also establish accommodation, caregiver, emergency, medication, and follow-up arrangements for the period after hospital-based treatment ends.

How Can International Patients Verify an Autologous Transplant Provider in Turkey?

International patients can verify health-tourism authorization through official records published by Turkey’s Ministry of Health. The current authorized-provider page is dated July 28, 2026. Health-tourism authorization does not confirm suitability for autologous transplantation or guarantee a clinical result. Patients should separately confirm that the hospital operates an appropriate hematopoietic stem cell transplant service. Turkish public centers document dedicated transplant wards, stem cell laboratories, and apheresis coordination for autologous procedures. Current Turkish rules also prohibit overt or covert healthcare advertising beyond permitted information. Regulatory status should therefore be evaluated separately from individualized transplant eligibility and informed consent.

Autologous Transplantation in Turkey Cost 2026: What Affects the Total Cost?

Autologous transplantation in Turkey has no single 2026 cost because treatment requirements differ substantially between individual patients. This page therefore does not provide a fixed treatment price. Costs can depend on pre-transplant testing, stem cell mobilization, apheresis, laboratory processing, and cryopreservation. Conditioning medicines, hospitalization, blood products, supportive medicines, and repeated laboratory monitoring can also influence the financial plan. Complications may create additional treatment requirements that cannot always be predicted beforehand. International patients should request an individualized written quotation after transplant assessment. The quotation should clearly identify collection, storage, medicines, hospitalization, monitoring, exclusions, and post-discharge services.

This content provides general medical information and does not recommend transplantation, a healthcare provider, or a clinical outcome. Autologous transplantation requires individualized assessment by appropriately qualified transplant professionals.

Last updated: August 14, 2026

Sources

• https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant

• https://www.cancer.gov/publications/dictionaries/cancer-terms/def/autologous

• https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html

• https://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html

• https://ankarasehir.saglik.gov.tr/EN-834597/adult-bone-marrow-center.html

• https://ankarasehir.saglik.gov.tr/EN-835043/pediatric-bone-marrow-transplant-center.html

• https://ankarasehir.saglik.gov.tr/EN-834593/hematology.html

• https://antalyaism.saglik.gov.tr/TR-359174/insan-doku-ve-hucrelerinden-elde-edilen-urunler-ve-bu-urunler-ile-ilgili-merkezler-hakkinda-yonetmelik.html

• https://shgmturizmdb.saglik.gov.tr/EN-69061/authorized-healthcare-providers-and-facilitators.html

• https://shgmturizmdb.saglik.gov.tr/EN-108974/regulation-on-international-health-tourism-and-tourist-health.html

• https://antalyaism.saglik.gov.tr/TR-366500/saglik-hizmetlerinde-tanitim-ve-bilgilendirme--faaliyetleri-hakkinda-yonetmelik.html